A marker, termed KIM-1, in the blood could be utilized to predict the risk of developing renal cell carcinoma.
Browsing: Disease Area > Endocrine
Find out more about Ti-Rads, guidelines for an ultrasound-based risk stratification system to identify nodules that merit biopsy or sonographic follow-up.
The US FDA has approved Progenics Pharmaceuticals’ Adzera®, a first-in-class treatment for two rare adrenal tumors: pheochromocytoma and paraganglioma.
A novel drug shows promise for preventing hearing loss in children after chemotherapy treatment for liver cancer.
A Phase III trial presented at ASCO has suggested that surgery might not be a necessity for patients suffering from advanced kidney cancer.
The FDA has approved the first immuno-oncology combination therapy for patients with advanced renal cell carcinoma.
In a landmark genetics study, a multi-institutional group of researchers have uncovered three distinct evolutionary paths for kidney cancer, allowing them to determine whether a tumor will be aggressive.
Eli Lilly have announced that Cyramza® has met its primary endpoint of overall survival, as well as its secondary goal of progression-free survival in late-stage liver cancer study.
To mark Rare Disease Day we recently spoke with Jonathan Wadsley (Weston Park Hospital, Sheffield, UK) about recent advancements in care for medullary thyroid cancer.
Recently at the 2018 ASCO-SIC Clinical immune-oncology symposium (CA, USA, 25-27 January) a panel discussed the science presented in a…